MELAN-A/MART-1 antigen expression in cutaneous and ocular melanomas

Maria Rita Nicotra, Paola Nisticò, Antonella Mangoni, Franco Di Filippo, Francesco Maria Marincola, Pier Giorgio Natali

Research output: Contribution to journalArticle


The human immune repertoire appears to be capable of recognizing normal antigens expressed by tumor cells. Among these antigens, those of differentiation, characterized by a restricted tissue expression, could be of clinical interest since they may represent a target for immunotherapeutic protocols. In this context we have evaluated, in benign and malignant lesions of the melanocytic lineage, the expression of the Melan-A/MART-1 antigen, which has been shown to be recognized by T cells, of HLA-A2 melanoma patients. The immunohistochemical analysis conducted with a Melan-A/MART-1 monoclonal antibody demonstrated that the antigen expression does not correlate with transformation or tumor progression. At variable levels MelanA/MART-1, differently from other differentiation antigens, is homogeneously expressed by multiple autologous metastases and by melanoma metastases at different body sites. This tissue distribution adds further biological support to the ongoing use of Melan-A/MART-I-related peptides in active immunotherapy.

Original languageEnglish
Pages (from-to)466-469
Number of pages4
JournalJournal of Immunotherapy
Issue number6
Publication statusPublished - 1997


  • Cutaneous melanomas
  • MART1
  • Ocular melanomas

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Fingerprint Dive into the research topics of 'MELAN-A/MART-1 antigen expression in cutaneous and ocular melanomas'. Together they form a unique fingerprint.

  • Cite this

    Nicotra, M. R., Nisticò, P., Mangoni, A., Di Filippo, F., Marincola, F. M., & Natali, P. G. (1997). MELAN-A/MART-1 antigen expression in cutaneous and ocular melanomas. Journal of Immunotherapy, 20(6), 466-469.